NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ariceum Therapeutics

Ariceum Therapeutics

Private
BerlinHealthcare & Life Scienceshttps://ariceum-therapeutics.com

Last Round

Series A

Extension

Apr 18, 2023

Total Funding Raised

$51.73M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Ariceum Therapeutics is a biotechnology company that develops targeted radiopharmaceutical therapies for the diagnosis and treatment of aggressive and hard-to-treat cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

radiopharmaceuticalstargeted radiotherapyPARP inhibitorprecision medicineoncologytheranosticssolid tumor treatmentclinical-stage biotechdrug discoverybiotech licensingtargeted alpha therapynuclear medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ariceum Therapeutics Comparables

Compare Ariceum Therapeutics with similar companies based on industry and business-model similarity.

Ariceum Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alpha-9 Oncology
83%
ARTBIO
81%
Convergent Therapeutics
77%

Ariceum Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionApr 18, 2023
Series AJun 8, 2022

Key People

Founding team and executive leadership

Manuel Sturzbecher-Hoehne

Chief Technology Officer, CTO

Executive Team

Susanna Mesa

Chief Operating Officer

Executive Team

Ariceum Therapeutics Investors

Notable investors and investment history

Ariceum Therapeutics investors
InvestorRounds
EQT Life SciencesSeries A
Andera PartnersSeries A Extension
HealthCapSeries A
Pureos BioventuresSeries A Extension, Series A
Earlybird Venture CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors grew 150% MoM, from 258 to 646.

  • Oct 14, 2025

    ATT001, a novel radiolabeled I-123 PARP inhibitor, is in development.

Ariceum Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ariceum Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ariceum Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBerlin
Employee Range12
Year Founded2021
Last FundingApr 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.